Agennix AG Secures EUR 15 Million Loan

PLANEGG/MUNICH, GERMANY and PRINCETON, NJ and HOUSTON, TX--(Marketwire - July 23, 2010) - Agennix AG (FRANKFURT: AGX) (XETRA: AGX) today announced that it has entered into an agreement with one of its major shareholders, dievini Hopp BioTech holding GmbH & Co. KG, pursuant to which dievini Hopp BioTech has provided a EUR 15.0 million loan to Agennix at an interest rate of 6% per annum. The loan agreement is unsecured and is repayable on thirty days advance notice, but not before October 15, 2010.

END OF AD HOC ANNOUNCEMENT

About Agennix
Agennix AG is a publicly listed biopharmaceutical company that is focused on the development of novel therapies to improve the length and quality of life of seriously ill patients in areas of major unmet medical need. The Company's most advanced program is talactoferrin, an oral therapy that has demonstrated activity in randomized, double-blind, placebo-controlled Phase II studies in non-small cell lung cancer, as well as in severe sepsis. Talactoferrin is currently in Phase III clinical trials in non-small cell lung cancer, and Agennix plans to develop this program further for the treatment of severe sepsis. Other clinical development programs include RGB-286638, a multi-targeted kinase inhibitor in Phase 1 testing; the oral platinum-based compound satraplatin; and a topical gel form of talactoferrin for diabetic foot ulcers. Agennix's registered seat is in Heidelberg, Germany. The Company has three sites of operation: Martinsried/Munich, Germany; Princeton, New Jersey and Houston, Texas. For additional information, please visit the Agennix Web site at www.agennix.com.

This ad hoc announcement contains forward-looking statements, which express the current beliefs and expectations of the management of Agennix AG. Such statements are based on current expectations and are subject to risks and uncertainties, many of which are beyond our control, that could cause future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Actual results could differ materially depending on a number of factors, and we caution investors not to place undue reliance on the forward-looking statements contained in this ad hoc announcement. Forward-looking statements speak only as of the date on which they are made and Agennix undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future.